Prachi Anand

Dr. Prachi Anand

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PAPrachi Anand
Prachi Anand
KMK.Y. Murali
K.Y. Murali
VTVibha Tandon
Vibha Tandon
PMP.S. Murthy
P.S. Murthy
RCRamesh Chandra
Ramesh Chandra

1 November 2008 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
PSPoonam Shokeen
Poonam Shokeen
PAPrachi Anand
Prachi Anand
YMY. Krishna Murali
Y. Krishna Murali
VTVibha Tandon
Vibha Tandon

3 August 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PAPrachi Anand
Prachi Anand
Alison L. O’NeilAlison L. O’Neil
Alison L. O’Neil
ELEmily Lin
Emily Lin
TDTrevor Douglas
Trevor Douglas
MHMandë Holford
Mandë Holford
The blood brain barrier (BBB) is often an insurmountable obstacle for a large number of candidate drugs, including peptides, antibiotics and chemotherapeutic agents. Devising an adroit delivery method to cross the BBB is essential to unlocking widespread application of peptide therapeutics. Presented here is an engineered nanocontainer for delivering peptidic drugs across the BBB encapsulating the analgesic marine snail peptide ziconotide (Prialt®). We developed a bi-functional viral nanocontainer based on theSalmonella typhimuriumbacteriophage P22 capsid, genetically incorporating ziconotide in the interior cavity and chemically attaching cell penetrating HIV-Tat peptide on the exterior of the capsid. Virus like particles (VLPs) of P22 containing ziconotide were successfully transported in several BBB models of rat and human brain microvascular endothelial cells (BMVEC) using a recyclable noncytotoxic endocytic pathway. This work demonstrates proof in principle for developing a possible alternative to intrathecal injection of ziconotide using a tunable VLP drug delivery nanocontainer to cross the BBB.

4 June 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HNHemlata Nimesh
Hemlata Nimesh
SSSouvik Sur
Souvik Sur
DSDevapriya Sinha
Devapriya Sinha
PYPooja Yadav
Pooja Yadav
PAPrachi Anand
Prachi Anand
VTVibha Tandon
Vibha Tandon

30 November 2007 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
PDF file
YMY. Murali
Y. Murali
PAPrachi Anand
Prachi Anand
VTV. Tandon
V. Tandon
RSR. Singh
R. Singh
RCR. Chandra
R. Chandra
PMP. Murthy
P. Murthy
The aqueous extract of the fruits of Terminalia chebula Retz. has been evaluated for its antidiabetic activity in streptozotocin (STZ) induced mild diabetic rats and compared with a known drug, tolbutamide. The oral effective dose (ED) of the extract was observed to be 200 mg/kg body weight, which produced a fall of 55.6% (p<0.01) in the oral glucose tolerance test. Oral administration of ED of aqueous extract of T.chebula (AETC) daily once for two months reduced the elevated blood glucose by 43.2% (p<0.01) and significantly reduced the increase in glycosylated hemoglobin (HbA1c) (p<0.01). The same dose also showed a marked improvement in controlling the elevated blood lipids as well as decreased serum insulin levels in contrast to the untreated diabetic animals. Hepatic and skeletal muscle glycogen content decreased by 75% and 62.9% respectively in diabetic controls, these alterations were partly prevented (34.9% and 21.17%) in AETC treated group when compared to the healthy controls. The in vitro studies with pancreatic islets showed that the insulin release was nearly two times more than that in untreated diabetic animals. The treatment did not have any unfavorable effect on other blood parameters of liver and kidney function tests. LD 50 was found to be above 3 g/kg bw i.e. 15 times of ED, because there were no deaths of animals even at this dose indicating high margin of safety. These findings suggest further investigations for the possible use of the aqueous extract of fruits of T.chebula for the treatment of diabetes.

19 April 2016 in Toxins
Verified
Journal Article
Open access
PDF file
AVAida Verdes
Aida Verdes
PAPrachi Anand
Prachi Anand
JGJuliette Gorson
Juliette Gorson
SJStephen Jannetti
Stephen Jannetti
PKPatrick Kelly
Patrick Kelly
MHMandë Holford
Mandë Holford
Animal venoms comprise a diversity of peptide toxins that manipulate molecular targets such as ion channels and receptors, making venom peptides attractive candidates for the development of therapeutics to benefit human health. However, identifying bioactive venom peptides remains a significant challenge. In this review we describe our particular venomics strategy for the discovery, characterization, and optimization of Terebridae venom peptides, teretoxins. Our strategy reflects the scientific path from mollusks to medicine in an integrative sequential approach with the following steps: (1) delimitation of venomous Terebridae lineages through taxonomic and phylogenetic analyses; (2) identification and classification of putative teretoxins through omics methodologies, including genomics, transcriptomics, and proteomics; (3) chemical and recombinant synthesis of promising peptide toxins; (4) structural characterization through experimental and computational methods; (5) determination of teretoxin bioactivity and molecular function through biological assays and computational modeling; (6) optimization of peptide toxin affinity and selectivity to molecular target; and (7) development of strategies for effective delivery of venom peptide therapeutics. While our research focuses on terebrids, the venomics approach outlined here can be applied to the discovery and characterization of peptide toxins from any venomous taxa.